WHO support to countries in the GAVI application process

1. WHO support to countries in the GAVI application process October 2012 WHO/IVB

2. Presentation Overview • WHO's role in the application process • Issues with the application process • Other issues of relevance

3. WHO's role in GAVI application process • Workshops & support (HQ & RO) • Application & cMYP revision workshops • In-country assistance • Remote assistance to develop applications • Updates on GAVI policies summarized and communicated • Pre-screening: add value to work with countries before final application is submitted to GAVI, enabling corrective action and improved applications. • Review application and supporting materials to check: • Data consistency between documents • Ensure that major GAVI requirements are met • F/U on missing information • Ensure that all key programmatic components are addressed • WHO Resource Persons - during review and liaise with respective focal points within WHO to obtain needed information

4. Issues with the application process

5. Application process • Deadline • Timing of application deadline & proximity to summer holidays made it difficult for WHO staff to engage with MoH staff to support the development of proposals • Issues with Online Platform • EVM reports not listed as mandatory (hitch with online portal) • WHO provided the reports on hand – GAVI following up to obtain remainder • Concern that this may be raised as a point by reviewers and final outcomes not be dependent on availability of EVM reports

6. Application form errors • Table 5.2 (Baseline and Annual Targets) • “Number of infants vaccinated (to be vaccinated) with 1st dose of TT+” – “infants” should be replaced with “number of pregnant women” • HPV introduction grant calculation • Maximum award is $2.4 per eligible girl, not per infant in the birth cohort. • Noted during pre-screening process – and has been corrected since – but may appear for applications that submitted before this error was noted

7. Country specific issue • South Sudan • Data with adjusted denominator was explained clearly in application • Application was endorsed and passed by ICC due to absence of NITAG (although NITAG is already formulated and pending ministerial order to complete the establishment)

8. Country specific requests for GAVI consideration • Application form - Signatures: • Section 4.1.3 on ICC composition can be omitted as this info available through APR or attaching a document with composition. • Laborious to write names and details of all members on online form. • Request you to consider that a similar arrangement be made for section 4.2 for NITAG composition. • Baseline & Annual Targets (Section 5.2) • Almost all data already provided to GAVI through APR • Unnecessary for repetition and mistake in any figure may lead to mismatch with APR data. • Request to consider linking this section on app form with section of APR (table 4) for same year

9. Other issues of relevance

10. Programme specific information • Rotavirus coverage • Age restrictions have been lifted, but some countries may still adhere to them • Countries may indicate similar projected coverage for rotavirus as DTP vaccine – however it will most probably be lower in reality due to age restrictions – either is acceptable • Gender & Sex Disaggregated data • Collection of this data is still very varied from country to country • Some countries may mention that gender is not an issue in their immunization programmes, i.e. all infants receive vaccines • WHO does not see this as a limitation to a successful application

11. Thank you

12. JRF Data On the WHO-UNICEF Joint Reporting Form (JRF), countries are given the opportunity to: • Describe any factor limiting the accuracy of the numerator (number of vaccinated children) or denominator (target population) • Provide: • Administrative coverage data • National official estimate • This is an opportunity for national authorities to provide estimates of what the most likely "true" coverage is (e.g. in case the admin coverage data is biased or inaccurate or does not include data from the private sector, etc.). • Survey data can also be used as a national official estimate • It is important to provide the justification and source for national coverage estimates.